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Abstract	  
Early	  monitoring	  of	  response	  to	  treatment	  is	  one	  of	  the	  cornerstones	  of	  personalized	  treatment.	  As	  
new	  and	  often	  expensive	  targeted	  therapies,	  which	  are	  tumoristatic	  rather	  than	  tumoricidal,	  become	  
available,	  new	  demands	  are	  posed	  on	  response	  assessment.	  Bevacizumab,	  an	  antiangiogenic	  agent	  
causing	  normalization	  of	   the	   tumor	  microvasculature,	  potentiates	   the	  effect	  of	  cytotoxic	   agents	  on	  
colorectal	  liver	  metastases.	  It	  is	  known	  that	  assessment	  of	  glucose	  metabolism	  by	  (dynamic)	  positron	  
emission	   tomography	   using	   [18F]-­‐fluoro-­‐2-­‐deoxy-­‐D-­‐glucose	   (18F-­‐FDG	   PET)	   can	   be	   used	   as	   an	   early	  
surrogate	   endpoint	   to	   determine	   treatment	   efficacy.	   Dynamic	   contrast	   enhanced	   magnetic	  
resonance	   imaging	   (DCE-­‐MRI)	   can	   be	   used	   to	   quantify	   functional	   tumor	   vasculature	   (permeability,	  
vascular	   surface	   area).	   Here,	   we	   describe	   the	   response	   of	   colorectal	   liver	  metastases	   to	   cytotoxic	  
regimens	   including	   bevacizumab	   using	   both	   18F-­‐FDG	   PET	   and	  DCE-­‐MRI	   in	   2	   cases.	   In	   both	   cases,	   a	  
large	   reduction	   in	  glucose	  metabolic	   rate	  and	   functional	   tumor	  vasculature	   is	  observed	  after	   three	  
treatment	  cycles.	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Introduction	  
Progress	   in	  cytotoxic	  treatment	  of	  advanced	  colorectal	  cancer	   (CRC),	  has	   improved	  median	  survival	  
from	   eight	   to	   more	   than	   20	   months.1	   For	   many	   tumor	   types	   it	   is	   known	   that	   they	   induce	  
neoangiogenesis,	   leading	   to	   an	   intratumoral	   microcirculation	   that	   is	   characterized	   by	   tortuous	  
microvessels	   with	   chaotic	   architecture	   and	   irregular,	   sluggish	   blood	   flow	   with	   unstable	   rheology.	  
Angiogenesis	   inhibitors	   lead	   to	   normalization	   of	   tumor	   vasculature	   which	   may	   improve	  
chemotherapy	  delivery.2	  In	  fact,	  the	  addition	  of	  bevacizumab	  to	  the	  standard	  first-­‐line	  chemotherapy	  
has	   improved	   response	   rate	   (34.8%	   to	   44.8%),	   progression-­‐free	   (6.2	   to	   10.6	   months)	   and	   overall	  
survival	   (15.6	   to	   20.3	   months)3-­‐6	   and	   this	   humanized	   monoclonal	   antibody	   against	   vascular	  
endothelial	   growth	   factor	   A	   (VEGF-­‐A)	   was	   approved	   for	   the	   treatment	   of	   metastatic	   colorectal	  
cancer.	   Unfortunately,	   not	   all	   patients	   respond	   to	   systemic	   treatment.	   Early	   response	   prediction	  
would	  help	  to	  identify	  patients,	  early	  in	  treatment,	  that	  most	  likely	  benefit	  from	  the	  addition	  of	  this	  
monoclonal	  antibody	  therapy,	  increasing	  the	  beneficial	  effects	  and	  preventing	  side	  effects	  and	  costs	  
due	  to	  ineffective	  treatments.	  
Capillary	  perfusion	  and	  permeability	  of	  the	  vessel	  wall	  can	  be	  measured	  in	  vivo	  by	  dynamic	  
gadopentetate	  dimeglumine	  (Gd-­‐DTPA)	  contrast-­‐enhanced	  magnetic	  resonance	  imaging	  (DCE-­‐MRI).7	  
Pharmacokinetic	   analysis	   of	   DCE-­‐MRI	   data	   using	   a	   2-­‐compartment	  model8,	   9	   yields	   parameters	   for	  
perfused	   capillaries	   including	   blood	   flow,	   permeability,	   and	   the	   total	   vessel	   surface	   area	   (Ktrans:	  
volume	  transfer	  constant,	  kep:	  compartmental	  rate	  constant,	  and	  ve:	  volume	  of	  contrast	  extravascular	  
extracellular	   space	   per	   unit	   volume	   of	   tissue).	   Assuming	   that	   vascularity,	   as	   reflected	   by	   these	  
parameters,	  is	  modified	  by	  treatment	  by	  bevacizumab,	  it	  may	  be	  hypothesized	  that	  these	  parameters	  
can	   be	   used	   for	   prediction	   of	   treatment	   response.	   The	   value	   of	   early	   monitoring	   of	   treatment	  
response	  by	  DCE-­‐MRI	  has	  been	  shown	  for	  rectal10	  and	  breast11-­‐13	  cancer.	  Glucose	  metabolic	  activity	  
can	   be	   assessed	   in	   vivo	   by	   positron	   emission	   tomography	   (PET)	   using	   the	   radionuclide	   labeled	  
glucose-­‐analogue	   [18F]-­‐fluoro-­‐2-­‐deoxy-­‐D-­‐glucose	   (18F-­‐FDG).14	   FDG	   uptake	   is	   increased	   in	   malignant	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tumors.	  An	  adequate	  vascular	  supply	  is	  necessary	  for	  delivery	  of	  glucose	  to	  tumor	  cells	  as	  well	  as	  the	  
presence	   of	   several	   membrane-­‐bound	   glucose	   transport	   proteins	   and	   intracellular	   hexokinase	   for	  
subsequent	   phosphorylation.	   FDG	   uptake	   can	   be	   quantified	   by	   pharmacokinetic	   compartment	  
modeling14,	   15	   of	   dynamic	   FDG-­‐PET	   data	   leading	   to	   glucose	  metabolic	   rates	   (MRglc).	   The	   predictive	  
value	  for	  early	  evaluation	  of	  treatment	  response,	  using	  changes	  in	  MRglc	  during	  (chemo)therapy,	  has	  
been	  shown	  in	  many	  tumor	  types	  including	  non-­‐small	  cell	  lung	  carcinoma16	  and	  CRC17.	  
Previously	  we	  have	  shown	  that	  the	  vascularity	  parameter	  kep,	  reflecting	  the	  transfer	  rate	  of	  
Gd-­‐DTPA	   over	   the	   capillary	   membrane,	   was	   inversely	   correlated	   to	   FDG-­‐uptake.18	   A	   positive	  
correlation	   was	   observed	   between	   kep	   and	   histopathological	   vascular	   density	   and	   in	   surgically-­‐
removed	  colorectal	  liver	  metastases	  (CRLM).	  More	  recently,	  we	  described	  the	  influence	  of	  cytotoxic	  
treatment	   on	   changes	   in	   vascular	   perfusion	   and	   permeability	   (DCE-­‐MRI)	   and	   cell	   metabolism	  
(dynamic	   18F-­‐FDG	  PET)	   showing	  no	   changes	   in	  Gd-­‐DTPA	   transfer	   rates	  but	  high	  decreases	   in	  MRglc,	  
which	  was	   correlated	   to	  patient	   survival.19,	   20	  Here	  we	  present	   findings	  of	   two	  patients	  with	  CRLM	  
imaged	  by	  both	  DCE-­‐MRI	  and	  18F-­‐FDG	  PET	  prior	  to	  and	  following	  3	  months	  of	  first-­‐line	  chemotherapy	  
including	  bevacizumab.	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Case	  reports	  
In	   patient	   A,	   a	   57	   year-­‐old	   male	   (Karnofsky	   Performance	   Status	   Score:	   90)	   with	   a	   history	   of	  
myocardial	  infarction,	  a	  T3N2Mx	  moderately	  differentiated	  adenocarcinoma	  of	  the	  sigmoid	  colon	  was	  
resected.	  CT	  at	  follow-­‐up	  showed	  two	  liver	  metastases,	  in	  Couinaud	  segment	  II/III	  (left)	  and	  VI	  (right),	  
considered	   eligible	   for	   resection.	  However,	   during	   surgery	   it	  was	   concluded	   that	   these	  metastases	  
were	  irresectable.	  The	  patient	  was	  treated	  by	  first-­‐line	  FOLFOX4	  therapy	  (bimonthly	  2-­‐h	   infusion	  of	  
oxaliplatin	   (85	   mg/m2)	   combined	   with	   weekly	   2-­‐h	   infusion	   of	   folinic	   acid	   (200	   mg/m2)	   and	   24-­‐h	  
continuous	   infusion	  of	  5-­‐fluorouracil	   (2600	  mg/m2))	  combined	  with	  bevacizumab	  (10	  mg/kg)	  30-­‐90-­‐
min	  infusion	  every	  3	  weeks.21	  Initial	  assessment	  after	  3	  treatment	  cycles	  by	  MRI	  showed	  stabilization	  
of	   disease	   (28%	   reduction	   according	   to	   the	   response	   evaluation	   criteria	   in	   solid	   tumors	   (RECIST	  
v1.022)).	  Compared	  to	  baseline,	  the	  dynamic	  18F-­‐FDG	  PET	  (performed	  3	  days	  after	  the	  last	  therapy	  day	  
of	   the	   3rd	   cycle	   as	   previously	   described20)	   showed	   a	   80%	   reduction	   in	   MRglc	   of	   the	   lesions	  
corresponding	   to	   a	   reduction	   in	   standardized	   uptake	   value	   (SUV,	   the	   activity	   concentration	   in	   the	  
tumor	  corrected	  for	  injected	  activity	  and	  patient	  body	  weight)	  on	  the	  static	  images	  of	  23%.	  The	  DCE-­‐
MRI	  performed	  the	  same	  day	  showed	  a	  clear	  decrease	  in	  Ktrans	  and	  kep	  of	  40%	  and	  58%	  respectively	  
(table	  1,	  figure	  1).	  
Due	  to	  polyneuropathy	  and	  therapy	  resistant	  diarrhea,	  oxaliplatin	  had	  to	  be	  stopped	  after	  9	  
cycles.	  After	  12	  cycles	   in	  total,	  stable	  disease	  on	  MRI	  persisted	  according	  to	  the	  RECIST-­‐criteria	  and	  
treatment	   was	   stopped.	   Six	   days	   after	   the	   last	   therapeutic	   day,	   the	   MRglc	   and	   SUV	   remained	   at	  
similarly	   reduced	   levels	   compared	   to	   baseline	   (reduction	   of	   89%	   and	   20%,	   respectively).	   The	   kep	  
however	  was	  only	  slightly	  lower	  than	  baseline	  and	  Ktrans	  had	  increased.	  
Follow-­‐up	  3	  months	  after	  the	  end	  of	  the	  previous	  treatment	  scheme,	  progressive	  disease	  was	  
observed,	  which	   did	   not	   respond	   to	   second-­‐line	   therapy	  with	   irinotecan.	   The	   patient	   died	   2	   years	  
after	  the	  start	  of	  chemotherapy,	  which	  is	  somewhat	  longer	  than	  the	  median	  overall	  survival	  known	  
for	  this	  treatment	  scheme.3	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Patient	   B,	   a	   58-­‐year	   old	  male	   (Karnofsky	   Performance	   Status	   Score:	   90)	  with	   a	   history	   of	   prostate	  
cancer	   treated	   by	   laparoscopic	   prostatectomy	   55	   months	   earlier,	   was	   diagnosed	   with	   a	   T3N2M1	  
poorly	  differentiated	  adenocarcinoma	   in	   the	   sigmoid.	  A	   low-­‐anterior	   resection	  with	  end	  colostomy	  
was	  performed.	  Palliative	  chemotherapy	  was	   started	   for	  multiple	   synchronous	  CRLM	  with	   first-­‐line	  
capecitabine	   orally	   (1000	  mg/m2	   twice	   daily	   on	   days	   1–14),	   combined	  with	   infusion	   of	   oxaliplatin	  
(130	  mg/m2	  on	  day	  1)	  and	  bevacizumab	  (7.5	  mg/kg	  on	  day	  1)	  plus	  cetuximab	  (400	  mg/m2	  in	  week	  1	  
of	  the	  first	  treatment	  cycle	  and	  250	  mg/m2	  weekly	  thereafter).23	  All	  cycles	  were	  administered	  every	  3	  
weeks.	   To	   prevent	   serious	   peripheral	   sensory	   neurotoxicity,	   oxaliplatin	  was	   administered	   during	   a	  
maximum	  of	  6	  cycles,	  after	  which	  the	  capecitabine	  dose	  was	   increased	  to	  1250	  mg/m2	  orally	  twice	  
daily.	  Initial	  assessment	  after	  3	  cycles	  by	  MRI	  showed	  a	  partial	  response	  (82%	  reduction	  according	  to	  
RECIST).	  Compared	  to	  baseline,	  the	  dynamic	  18F-­‐FDG	  PET	  (performed	  the	  day	  after	  the	   last	  therapy	  
day	  of	  the	  3rd	  cycle)	  a	  90%	  reduction	  in	  MRglc	  of	  the	  lesions	  was	  seen	  corresponding	  to	  a	  reduction	  in	  
SUV	  on	  the	  static	  images	  of	  24%.	  The	  DCE-­‐MRI	  performed	  the	  same	  day	  showed	  a	  clear	  decrease	  in	  
Ktrans	  and	  kep	  of	  93%	  (table	  1,	  figure	  2).	  	  
Follow-­‐up	  after	  9	  cycles	  of	  chemotherapy	  by	  MRI	  showed	  a	  complete	  response	  according	  to	  
RECIST.	   The	   dynamic	   18F-­‐FDG	   PET	   (performed	   the	   day	   after	   the	   last	   therapy	   day	   of	   the	   9th	   cycle)	  
showed	  a	  further	  reduction	  of	  MRglc	  with	  96%	  compared	  to	  baseline,	  the	  SUV	  remained	  stable	  at	  22%	  
below	  baseline	  (table	  1).	  Unfortunately,	  the	  DCE-­‐MRI	  performed	  that	  day	  could	  not	  be	  analyzed	  due	  
to	  a	  human	  mistake	  in	  saving	  the	  images.	  
After	   17	   cycles	   this	   treatment	   regimen	  was	   discontinued	   due	   to	   the	   development	   of	   lung	  
metastases	  and	  cetuximab-­‐related	  skin	  toxicity.	  Less	  than	  30%	  of	  patients	  on	  this	  treatment	  scheme	  
have	  a	  progression-­‐free	  survival	  of	  this	  duration.23	  After	  the	  5th	  cycle	  of	  second-­‐line	  treatment	  with	  3-­‐
weekly	   irinotecan,	   treatment	   was	   switched	   to	   oxaliplatin	   combined	   with	   capecitabine	   due	   to	   a	  
peritonitis	  carcinomatosis.	  Despite	  treatment	  the	  disease	  remained	  progressive	  and	  the	  patient	  died	  
Page	  8	  of	  17	  
	  
21	   months	   after	   the	   start	   of	   chemotherapy.	   His	   overall	   survival	   was	   comparable	   to	   the	   median	  
survival	  of	  this	  treatment	  scheme	  (19.4	  months).23	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Discussion	  
In	  this	  case	  series	  of	  2	  patients	  treated	  with	  bevacizumab-­‐containing	  therapeutic	  regimens	  we	  saw	  a	  
strong	  decrease	  in	  vessel	  perfusion	  and	  permeability	  as	  assessed	  by	  DCE-­‐MRI.	  These	  results	  suggest	  
that	  DCE-­‐MRI	  can	  be	  used	  to	  assess	  tumor	  response	  to	  vascular	  targeting	  therapy.	  In	  contrast,	  in	  23	  
other	  patients	  with	  CRLM	  treated	  with	  cytotoxic	   (non-­‐targeting)	  chemotherapeutic	  agents,	  we	  saw	  
similar	  responses	  in	  glucose	  metabolism,	  which	  were	  correlated	  with	  patient	  overall	  and	  progression-­‐
free	  survival.20	  However,	  in	  that	  study	  no	  changes	  in	  DCE-­‐MRI	  parameters	  were	  observed.	  
To	   the	   best	   of	   our	   knowledge,	   this	   is	   the	   first	   report	   of	   clinical	   response	   monitoring	   of	  
antiangiogenic	   treatment	   of	   CRLM	  with	   bevacizumab	  by	  DCE-­‐MRI,	   excluding	   therapy	  with	   tyrosine	  
kinase	   inhibitors.	   Wedam	   et	   al.24	   showed	   in	   20	   patients	   with	   inflammatory	   and	   locally	   advanced	  
breast	   cancer	   that	   treatment	   with	   bevacizumab	   for	   1	   cycle	   followed	   by	  
bevacizumab/doxorubicin/docetaxel	  for	  6	  cycles	  reduced	  vascular	  parameters	  quantified	  by	  DCE-­‐MRI	  
with	  Gd-­‐DTPA.	  From	  baseline	  to	  the	  end	  of	  the	  first	  cycle	  (bevacizumab	  alone)	  they	  saw	  a	  decrease	  in	  
kep,	   Ktrans	   and	   ve	   of	   58.0%,	   49.4%	   and	   20.4%,	   respectively.	   After	   7	   cycles	   in	   total,	   these	   decreased	  
further,	   being	   75.5%,	   59.1%	   and	   20.2%	   compared	   to	   baseline.	   However,	   they	   could	   not	   find	   a	  
significant	   difference	   in	   any	   of	   the	   DCE-­‐MRI	   parameters	   comparing	   clinical	   responders	   with	  
nonresponders.	   Thukral	   et	   al.13	   followed	  19	  patients	  with	   inflammatory	   or	   locally	   advanced	  breast	  
cancer	   treated	   with	   1	   cycle	   of	   bevacizumab	   alone	   followed	   by	   6	   cycles	   of	   bevacizumab	   added	   to	  
chemotherapy	   using	   DCE-­‐MRI	   with	   Gd-­‐DTPA.	   The	   median	   values	   of	   Ktrans,	   kep	   and	   the	   integrated	  
(180s)	  area	  under	  the	  concentration-­‐time	  curve	  (IAUC180)	  showed	  significant	  decreases	  from	  baseline	  
to	   cycle	   1	   of	   34%	   (p=.003),	   15%	   (p<.001)	   and	   23%	   (p=.009),	   respectively.	   Similarly,	   Baar	   et	   al.25	  
recently	  showed	  that	  bevacizumab	  decreases	  tumor	  perfusion	  as	  measured	  by	  DCE-­‐MRI.	  Forty-­‐nine	  
patients	  with	  inoperable	  breast	  cancer	  were	  randomized	  to	  either	  2	  cycles	  of	  neoadjuvant	  docetaxel	  
weekly	   for	  6	  weeks	  or	  docetaxel/bevacizumab	  every	  other	  week	   for	  16	  weeks.	  DCE-­‐MRI	  using	  Gd-­‐
DTPA	  was	  performed	  at	  baseline	  and	  after	  the	  first	  and	  second	  treatment	  cycle.	  All	  patients	  showed	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a	  decrease	  in	  IAUC90	  which	  was	  larger	  for	  patient	  using	  docetaxel/bevacizumab	  than	  patients	  treated	  
with	   docetaxel	   alone	   (p=0.024).	   This	   decrease	  was	  more	   profound	   after	   2	   than	   after	   1	   treatment	  
cycle.	  
Therapy	  response	  assessment	  using	  DCE-­‐MRI	  therefore	  shows	  variable	  results,	  depending	  on	  
the	   treatment	   schedule	   used,	   contrast	  medium	   administered	   and	   analysis	   performed	   (heuristic	   or	  
compartment	   analysis)	   and	   may	   even	   differ	   between	   different	   tumors.	   As	   these	   2	   cases	   are	  
illustrative	   of	   treatment	   response	   assessment	   by	   DCE-­‐MRI,	   larger	   trials	   should	   be	   performed	   to	  
assess	   its	   true	   value	   and	   to	   determine	   the	   most	   useful	   parameter	   and	   optimal	   time-­‐point	   for	  
evaluation.	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Tables	  
	   Baseline:	   3	  cycles:	   Late:	  
Patient	  A:	   	   	   	  
FDG-­‐PET:	   	   	   	  
-­‐	  MRglc	  [nmol/min/cm3]	   91.7	   18.4	   (-­‐80%)	   10.1	   (-­‐89%)	  
-­‐	  SUV	  [g/cm3]	   5.3	   4.1	  	   (-­‐23%)	   4.2	   (-­‐20%)	  
DCE-­‐MRI:	   	   	   	  
-­‐	  Ktrans	  [/s]	   0.0156	   0.0094	   (-­‐40%)	   0.0183	   (+17%)	  
-­‐	  kep	  [/s]	   0.0304	   0.0127	   (-­‐58%)	   0.0295	   (-­‐3%)	  
Survival:	   	   	   	  
-­‐	  PFS	  [months]	   9.1	  	   	   	  
-­‐	  OS	  [months]	   26.8	  	   	   	  
	   	   	   	  
Patient	  B:	   	   	   	  
FDG-­‐PET:	   	   	   	  
-­‐	  MRglc	  [nmol/min/cm3]	   80.4	   7.8	   (-­‐90%)	   3.2	   (-­‐96%)	  
-­‐	  SUV	  [g/cm3]	   4.3	   3.2	   (-­‐24%)	   3.4	   (-­‐22%)	  
DCE-­‐MRI:	   	   	   	  
-­‐	  Ktrans	  [/s]	   0.0895	   0.0064	   (-­‐93%)	   NA	  
-­‐	  kep	  [/s]	   0.122	   0.0086	   (-­‐93%)	   NA	  
Survival:	   	   	   	  
-­‐	  PFS	  [months]	   13.8	   	   	  
-­‐	  OS	  [months]	   23.2	   	   	  
Table	   1:	   Responses	   in	   imaging	   parameters	   of	   the	   2	   patients	   described	   between	   baseline,	   after	   3	  
treatment	   cycles	   and	   a	   late	   acquisition	   (12	   cycles	   for	   patient	   A,	   9	   cycles	   for	   patient	   B).	   Relative	  
changes	   compared	   to	   the	   baseline	   scan	   are	   displayed	   between	   brackets.	   DCE-­‐MRI:	   dynamic	  
gadopentetate	   dimeglumine	   contrast	   enhanced	   MRI;	   FDG-­‐PET:	   [18F]-­‐fluoro-­‐2-­‐deoxy-­‐D-­‐glucose	  
positron	   emission	   tomography;	   kep:	   compartmental	   rate	   constant;	   Ktrans:	   volume	   transfer	   constant;	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MRglc:	  glucose	  metabolic	  rate;	  NA:	  not	  available;	  OS:	  overall	  survival;	  PFS:	  progression-­‐free	  survival;	  
SUV:	   standardized	   uptake	   value	   (the	   activity	   concentration	   in	   the	   tumor	   corrected	   for	   injected	  
activity	  and	  patient	  body	  weight).	  




Figure	  1:	  Patient	  A.	  Static	  [18F]-­‐fluoro-­‐2-­‐deoxy-­‐D-­‐glucose	  positron	  emission	  tomography	  acquired	  40-­‐
50	  minutes	  after	  injection	  of	  the	  tracer	  (left	  panels).	  Enhanced	  T1	  (middle	  panels)	  and	  parametric	  kep	  
(right	  panels)	  DCE-­‐MRI	   images.	  From	  top	  row	  (baseline)	  via	  middle	  row	  (after	  1	  treatment	  cycle)	  to	  
lower	  row	  (after	  12	  cycles	  of	   therapy)	   it	  can	  be	  clearly	  seen	  that	  glucose	  metabolism	  as	  well	  as	  kep	  
decrease	  in	  the	  lesion	  displayed	  (Couinaud	  segment	  VII	  (arrow)).	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Figure	  1:	  Patient	  B.	  Static	  [18F]-­‐fluoro-­‐2-­‐deoxy-­‐D-­‐glucose	  positron	  emission	  tomography	  acquired	  40-­‐
50	  minutes	  after	  injection	  of	  the	  tracer	  (left	  panels).	  Enhanced	  T1	  (middle	  panels)	  and	  parametric	  kep	  
(right	  panels)	  DCE-­‐MRI	   images.	  From	  top	  row	  (baseline)	  via	  middle	  row	  (after	  1	  treatment	  cycle)	  to	  
lower	   row	   (after	   9	   cycles	  of	   therapy)	   it	   can	  be	   clearly	   seen	   that	   glucose	  metabolism	  as	  well	   as	   kep	  
decrease	   in	   the	   2	   lesions	   displayed	   (Couinaud	   segments	   IVa	   (arrowhead)	   and	   VII	   (arrow)).	   Due	   to	  
technical	  problems	  no	  MRI	  data	  was	  available	  for	  this	  patient	  after	  9	  cycles	  of	  therapy.	  
	  


